Cereno Scientific discusses phase IIa results for CS1
Cereno Scientific discusses phase IIa results for CS1
3 October, 2024
The trial was made with the company’s lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension.
See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.